Full-Time

Data Quality Stewardship Specialist

Data Quality Stewardship

Posted on 8/14/2026

Deadline 8/15/26
Merck

Merck

10,001+ employees

Pharmaceutical company developing medicines and vaccines

No salary listed

Hyderabad, Telangana, India

Hybrid

Hybrid work arrangement; domestic relocation is indicated.

Bachelor's, Master's

Category
Data & Analytics (1)
Required Skills
Power BI
Microsoft Azure
Agile
Python
Airflow
Data Visualization
Git
SQL
Machine Learning
ETL
AWS
Data Governance
Databricks
Data Analysis
Snowflake

Get referred to Merck

See people who can refer or advise you

Requirements
  • A Bachelor's or Master's degree in Computer Science, Information Technology, Data Management, or a related field, or equivalent experience.
  • At least 5 years of experience in data quality or related technology roles.
  • Strong Structured Query Language (SQL) skills.
  • Experience with data profiling, issue management, and root-cause analysis.
  • Familiarity with master data management, reference data, and metadata concepts.
  • Experience with data transformation routines, including extract, transform, and load (ETL) or extract, load, and transform (ELT) processes.
  • Familiarity with medallion architecture and cloud data platforms such as Snowflake and Databricks.
  • Experience with application programming interface (API) integration and Airflow.
  • Familiarity with Agile methodologies and sprint-based delivery.
  • Strong analytical thinking, problem-solving, documentation, and attention to detail.
  • Experience with Collibra Data Quality, data visualization tools such as Power BI, and data observability tools such as Great Expectations and Acceldata.
  • Familiarity with data governance, stewardship operating models, or the DAMA-DMBOK framework.
  • Familiarity with regulated industries such as healthcare, life sciences, finance, or manufacturing.
  • Experience working in a global or matrixed organization.
  • No visa sponsorship is available for the position.
Responsibilities
  • Work with divisional partners to onboard their data to the enterprise data quality platform.
  • Support platform adoption within business teams and promote consistent usage.
  • Understand divisional requirements and configure and implement them within the data quality platform.
  • Serve as a liaison between business data owners, information technology, and the Chief Data and Analytics Office to align data quality priorities.
  • Train users on the data quality platform and encourage consistent, effective usage.
  • Contribute to the development and documentation of platform standards, operating procedures, and best practices.
  • Maintain accurate documentation of processes, rules, and controls.
  • Create, maintain, and enhance data quality rules and checks.
  • Develop and execute data quality routines, validations, and monitoring controls.
  • Partner with Chief Data and Analytics Office teams to align data quality rules with enterprise data policies and standards.
  • Define, measure, and report data quality key performance indicators across domains.
  • Develop and maintain data quality dashboards and scorecards for leadership visibility.
  • Track trends and provide insights to prioritize data quality improvement initiatives.
  • Review data quality reports and identify issues, trends, anomalies, and opportunities for improvement.
  • Investigate data quality issues, perform root-cause analysis, and coordinate remediation with relevant stakeholders.
  • Communicate findings with divisional stakeholders and support remediation efforts.
  • Facilitate data quality issue-resolution discussions with cross-functional stakeholders.
  • Maintain a data quality issue log, track resolution progress, and ensure timely closure.
  • Define and follow escalation paths for critical data quality issues impacting downstream processes.
  • Support adherence to service-level agreements for data quality issue resolution.
  • Ensure data quality practices align with applicable regulatory requirements and documentation, including GxP, the Food and Drug Administration, and the European Medicines Agency.
  • Support audit readiness by maintaining traceability of data quality rules, controls, and remediation actions.
  • Develop automation utilities to improve monitoring, reporting, and operational efficiency.
  • Apply analytical thinking and problem-solving to resolve complex data issues.
  • Promote a culture of data quality, accountability, and continuous improvement.
Desired Qualifications
  • Familiarity with the DAMA-DMBOK framework or a Certified Data Management Professional certification.
  • Exposure to artificial intelligence and machine learning data quality considerations, such as training data quality.
  • Experience in a global or matrixed organization.
  • Experience with data visualization tools such as Power BI.
  • Experience with data observability tools such as Great Expectations and Acceldata.

Merck is a global healthcare company that develops medicines, vaccines, and animal health products. It advances long-term health by conducting research and development to create new treatments for diseases such as cardiovascular disease, diabetes, and cancer, then brings these medicines to patients, healthcare professionals, and institutions worldwide. The company’s products work by undergoing scientific discovery, clinical testing, and regulatory approval before being manufactured and sold or distributed through patient assistance programs. What sets Merck apart is its large, diversified portfolio across human medicines, vaccines, and animal health, along with a strong emphasis on R&D, global reach, and support services like Merck Connect and Merck Manuals that provide professional resources. Merck’s goal is to tackle major health threats by applying science to discover and deliver therapies that improve patient outcomes and public health across the globe.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kenilworth, Illinois

Founded

1891

Get referred to Merck

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • LIPFENDRA won FDA approval in July 2026, opening a first-in-class oral PCSK9 market.
  • ENFLONSIA gained Japan and China approvals in August 2026, widening infant RSV reach.
  • SCRI and Merck expanded community oncology trials on August 14, 2026, boosting enrollment.

What critics are saying

  • Keytruda patents start expiring in 2028, and Merck models U.S. sales declines immediately.
  • Terns cost Merck $5.8 billion in Q2 2026, crushing EPS and discipline.
  • Tulisokibart failed SSC-ILD in August 2026, leaving Merck vulnerable if UC disappoints.

What makes Merck unique

  • Merck’s oncology engine still centers on Keytruda family, driving $8.4 billion in Q2 2026.
  • Keytruda Qlex’s April 2026 J-code shows faster US conversion than peers.
  • Merck’s 2026 pipeline spans vaccines, oral PCSK9, RSV, and TL1A across multiple franchises.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-20%

1 year growth

-20%

2 year growth

-20%
GeekWire
Aug 14th, 2026
InduPro raises $77M, begins first human trial of cancer drug.

InduPro raises $77M, begins first human trial of cancer drug. by John Cook on Aug 14, 2026 at 6:33 am InduPro, a 4-year-old biotech startup with operations in Seattle and Cambridge, Mass., this week announced $77 million in series B funding as it begins a Phase 1 clinical trial of its lead cancer drug candidate. The company said that the first patient has been dosed in the trial of IDP-001, an experimental antibody-drug conjugate designed to target cancer cells through a combination of two proteins on their surface. The early-stage trial is enrolling adults with advanced or metastatic non-small cell lung cancer and other solid tumors whose disease has progressed following standard treatment. Researchers will evaluate the drug's safety, tolerability, drug behavior and early signs of antitumor activity. InduPro is developing drugs based on the spatial relationships between proteins on the surface of cells. The company says its approach can identify combinations of targets that are close together on cancer cells but not on normal tissue, potentially allowing drugs to more selectively attack tumors. The Series B was led by The Column Group, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi and Eli Lilly and Company. "We are delighted to have the support of this outstanding group of life sciences investors and strategic partners who recognize the potential of our proximity-guided platform to create precision therapeutics in oncology and autoimmune disease," said InduPro CEO Prakash Raman in a press release. Raman is a longtime biopharma executive who previously served as president and CEO of Ribon Therapeutics. Before that, he spent nearly 14 years at Novartis, where he served as vice president and global head of business development and licensing for the Novartis Institutes for Biomedical Research. The company's president and chief scientific officer is Scott Lesley, who previously served as vice president of discovery biologics at Merck. InduPro said the new funding will support the Phase 1 development of IDP-001 and further development of its preclinical pipeline, which includes programs targeting cancer and autoimmune diseases. Earlier this year, InduPro inked a strategic collaboration and licensing agreement with Eli Lilly covering up to three oncology targets, a deal worth up to approximately $950 million.

Yahoo
Aug 14th, 2026
SCRI and MSD to broaden US oncology trial access.

SCRI and MSD to broaden US oncology trial access. Salong Debbarma Updated Fri, August 14, 2026 at 2:46 AM PDT Sarah Cannon Research Institute (SCRI) and Merck & Co (MSD) have entered a collaboration aimed at increasing patient access to oncology clinical trials at community sites across the US. The partnership will utilise SCRI's Accelero delivery model, which is designed to improve both the reach and efficiency of cancer studies. MSD and SCRI are seeking to address the increasing complexity of oncology clinical studies, which require more precise patient selection and faster access to new therapies. The organisations aim to implement new approaches for trial delivery that are efficient, use advanced data methods, and can be integrated within local communities. MSD Research Laboratories associate vice-president and North America global clinical trial operations head Jennifer Coppola said: "At MSD, we are focused on advancing research to better understand cancer and potential therapeutic approaches. "By leveraging the Accelero delivery model, we have the potential to reach patients faster, reduce protocol complexity, and make oncology clinical studies more accessible in the communities where patients live." The Accelero model employed by SCRI includes accelerated trial site start-up, electronic data transfer systems connecting electronic health records (EHR) and case report forms, and initiatives to boost recruitment. Collaborations using Accelero have reported trial site activations up to 50% faster than conventional approaches, with enrolment rates 19% higher than the national average of 7%, and 95% fewer changes to data compared to standard processes. SCRI runs a network comprising around 1,500 oncology physicians, offering access to clinical studies at over 200 sites in more than 20 US states. The group reports involvement in over 900 first-in-human clinical trials since its formation. In October 2024, Exelixis and MSD partnered to assess the potential of combining their respective cancer therapies in upcoming trials. "SCRI and MSD to broaden US oncology trial access" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Yahoo Finance
Aug 12th, 2026
Merck Q2 revenue beats at $16.6B but lowers full-year EPS guidance by 47%

Merck reported second-quarter revenue of $16.61 billion, beating analyst estimates of $16.27 billion with 5.1% year-on-year growth. The pharmaceutical company's performance was driven by strong sales of KEYTRUDA in oncology and robust Animal Health results. The company raised its full-year revenue guidance to $66.8 billion at the midpoint but lowered adjusted earnings per share guidance to $2.71, a 46.9% decrease. Operating margin fell to -3.5% from 31.6% in the prior year, affected by higher operating expenses and acquisition-related charges. During the earnings call, analysts questioned management about planned clinical trials for pembrolizumab in first-line lung cancer, TL1A activity compared to TNF inhibitors, and commercial adoption expectations for LIPFENDRA. CEO Robert Davis highlighted expansion opportunities for oral PCSK9 treatments in primary care markets.

The Indian Express (P) Limited
Aug 11th, 2026
Merck expands Singapore lab for biopharma testing.

Merck expands Singapore lab for biopharma testing. Paolo Carli highlights how the expansion will support analytical and biosafety testing services for Asia Pacific biopharma customers. Merck is expanding its Singapore laboratory to strengthen analytical and biosafety testing services for customers across the Asia Pacific region. Biosafety testing is a step in the drug development and manufacturing process, helping to ensure that biologics are safe, effective and compliant with regulatory requirements. The expansion builds on Merck's global testing expertise of more than 75 years and marks a milestone in providing a local contract testing services portfolio for the region's growing biopharma industry. "Localizing these BioReliance testing capabilities means our Asia Pacific biopharma customers can accelerate their development timelines, improve operational efficiency, and meet evolving regulatory and sustainability standards" said Paolo Carli, Head of Advanced Solutions for the Life Science business of Merck. "This investment underscores Merck's commitment to empowering medicine makers by providing industry-leading analytical and biosafety testing services and technical expertise." Merck's Singapore laboratory will become the first BioReliance facility in Asia-Pacific to offer both Cell Line Characterization services and GMP next-generation sequencing (NGS) capabilities. It will also offer molecular methods including Blazar(R), a proprietary platform for rapid virus detection. The expanded facility aims to support the industry's move towards quality control testing of biologics and 3Rs (Replacement, Reduction, and Refinement of animal use) through molecular methods. "Merck's expansion of the BioReliance lab will bring world-class and next-generation testing services to biopharmaceutical companies in Singapore and the region. We look forward to continuing our partnership with Merck to strengthen Singapore's ecosystem, build new capabilities within our local workforce, and enable the delivery of innovative therapies to patients," said Goh Wan Yee, Senior Vice President and Head of Healthcare, Singapore Economic Development Board. The Singapore BioReliance(R) lab was opened in 2018, and the expansion will bring the total lab area to over 1,000 square metres. The expansion is also a step in Merck's broader strategy to support the region's life science ecosystem and drive scientific progress.

Retorio
Aug 10th, 2026
How Merck's commercial teams build their own AI role-play, market by market.

How Merck's commercial teams build their own AI role-play, market by market. Munich, August 10, 2026 Merck x Retorio · Pharmaceuticals There is a limit to how far generic training travels. A rep in Boston does not face the same conversation as a rep in Madrid or São Paulo, and a scenario built for one product rarely fits another. Merck works with Retorio on something more powerful than off-the-shelf practice: the ability for its commercial teams to build their own realistic role-play, shaped around the products, stakeholders and situations they actually face. Retorio supports that work across 19 markets, including the United States, where Merck operates as EMD Serono. Relevance is what makes practice stick The teams that get the most from coaching are the ones whose practice mirrors reality. A generic exercise is easy to dismiss; a scenario that sounds exactly like next week's meeting is impossible to ignore. But building relevant, high-quality practice used to require experts and weeks of work, so most teams settled for generic. Merck's commercial teams wanted more control: to turn their own materials and personas into practice that reflects their market and their language. A US field team preparing for a payer conversation and a European team preparing for a hospital specialist need the same coaching standard, not the same script. Coaching teams can shape themselves Teams create custom scenarios with virtual stakeholders, and the platform delivers instant, behavioral feedback based on the Warmth and Competence framework. Reps rehearse their approach, adapt to different conversation styles and refine how they communicate value, in a private, on-demand environment. The result is practice that feels real because it is theirs, tuned to the specific conversations a team is about to have. Consistency and control together For a global science and technology company, adapting scenarios per market and language while keeping one consistent coaching standard is exactly what makes the approach scale across 19 markets. In practice: Picture an EMD Serono team in the US that wants to flip the usual exercise on its head, letting reps play the customer as well as the seller, with their own products and their own market's access questions. They build the scenario in Retorio, run it across the team and refine it from real feedback. Practice stops being something done to them and becomes something they own. The platform runs on EU-hosted infrastructure that is GDPR and DSGVO compliant, EU AI Act aligned and ISO 27001 certified, which is the bar pharmaceutical teams have to meet. A partnership Retorio is proud of As Merck's commercial teams keep raising the bar, the ability to build their own realistic practice puts capability in their hands. Retorio is glad to give them the tools. Retorio is an AI coaching platform for enterprise commercial teams in insurance, pharmaceuticals, telecommunications, food and automotive. GDPR and DSGVO compliant, EU AI Act aligned, ISO 27001 certified, hosted on Google Cloud Platform with EU data residency. The Retorio News Team The Retorio News Team covers product updates, AI coaching insights, and data trends from across the Retorio platform.

INACTIVE